Testing

Autoimmune neurological disorders can often be treated, sometimes with full restoration of function. However, because the symptoms mimic other conditions, autoimmune neurological disorders are frequently misdiagnosed, resulting in an irreversible loss of function.

By Barbara J. Toman • February 11, 2019

Ann Moyer, M.D., Ph.D., gives an overview of the inflammatory bowel disease primary immunodeficiency testing available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Emily Linginfelter • February 5, 2019

numares and Mayo Clinic Laboratories have announced a collaboration to develop clinical diagnostic tests that will measure clusters of risk factors as opposed to individual biomarkers. The unique testing will use nuclear magnetic resonance technology, focusing on cardiovascular disease, kidney disease and liver cancer—among a few other specific diseases.

By gmchiri • February 5, 2019

In close collaboration with our logistics providers, we have determined that clients can now safely send all specimens to Rochester now that temperatures have moderated. Thank you for your patience and understanding.

By Andy Tofilon • January 30, 2019

John Lieske, M.D., gives an overview of the phospholipase A2 receptor antibodies testing available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

By Alyssa Frank • January 18, 2019

A movement disorder might be caused by the body’s immune system, which is meant to fight infections, suddenly attacking the brain. Fortunately, an “autoimmune movement disorder” can often be treated—once its cause is discovered.

By Christoph Bahn • January 17, 2019

In December 2018, Mayo Clinic Laboratories announced four new tests along with numerous reference value […]

By Emily Linginfelter • January 10, 2019

In November 2018, Mayo Clinic Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

By Emily Linginfelter • December 13, 2018

Christopher Klein, M.D., and Erik Thorland, Ph.D., give an overview of the new hereditary epilepsy panels available through Mayo Clinic Laboratories. They discuss the Mayo Clinic testing approach, interpretation and results, and custom gene ordering.

By Alyssa Frank • December 4, 2018

Visit us at booth #2927 at the American Society of Hematology in San Diego from Saturday, December 1 through Monday, December 3 to discuss how our state-of-the-art hematology testing can integrate with your practice.

By mayocliniclabs • November 29, 2018

David Murray, M.D., Ph.D., provides an overview of the updated monoclonal gammopathy screening and monitoring tests for multiple myeloma. He discusses when this testing should be ordered, how this approach improves upon previous methods, and what clinical action can be taken from the results of these tests.

By Alyssa Frank • November 28, 2018

In October 2018, Mayo Medical Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

By Alyssa Frank • November 13, 2018

Robert Jenkins, M.D., Ph.D., a pathologist and cancer geneticist at Mayo Clinic, provides an overview of the new neuro-oncology expanded gene panel and chromosomal microarray testing available through Mayo Medical Laboratories. He discusses which types of patients should be tested, how these tests improves upon previous methods, and what clinical action can be taken from the results of this testing.

By Alyssa Frank • November 12, 2018